Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
359 Results Found
Administration actions target health care competition, lower drug costs
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs.
Broadlawns Medical Center | Iowa
Broadlawns Medical Center of Des Moines treats a diverse population of patients, addressing the medical, societal, and behavioral health needs of local citizens – from the greater Des Moines area – serving more than 72,757 patients in fiscal year 2022.
AHA Comments on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
AHA comments on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act.
CMS: Makers of selected drugs agree to participate in Medicare price negotiation
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced.
FDA seeks comments on updated labeling guidance for biosimilar products
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products.
CMS releases fact sheet on Medicare drug price negotiation process
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price Negotiation Program, its process for negotiating with the companies that make the drugs, opportunities for public input and key dates for implementation.
Administration announces first Medicare drug negotiation list
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs.
Will Blue Shield’s New Pharma Model Disrupt the PBM Market?
A new plan will transition Blue Shield of California’s drug supply management from CVS Health’s PBM to five companies — a move the payer believes will save its 4.8 million members as much as $500 million a year in drug costs or about 10% to 15% of what it spends on drugs annually.
Drug prices weigh heavily on employers’ minds, according to new study
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are concerned about high-cost drugs in the pipeline, with 91% reporting concern about pharmacy cost trends overall.
CMS revises initial guidance on Medicare drug price negotiation
The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to negotiate Medicare prices with makers of certain high-cost, single-source drug and biological products in 2023 and 2024 for prices effective in 2026.